Kura Oncology (KURA) Non-Current Debt (2014 - 2026)

Kura Oncology (KURA) has 12 years of Non-Current Debt data on file, last reported at $9.7 million in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 27.44% year-over-year to $9.7 million in Q1 2026; TTM through Mar 2026 was $9.7 million, a 27.44% increase from a year earlier, with the FY2025 full-year figure at $9.7 million, up 40.41% from the prior year.
• Non-Current Debt for Q1 2026 stood at $9.7 million, roughly flat from $9.7 million in the prior quarter.
• Over the last five years, Non-Current Debt for KURA reached as high as $9.7 million in Q1 2026 and fell as low as $5.3 million in Q3 2025.
• Historically, Non-Current Debt has averaged $8.4 million across 5 years, with a median of $9.2 million in 2022.
• On a YoY basis, Non-Current Debt climbed as much as 40.41% in 2025 and fell as far as 31.21% in 2025.
• Year by year, Non-Current Debt stood at $9.2 million in 2022, then climbed by 1.9% to $9.3 million in 2023, then slipped by 25.89% to $6.9 million in 2024, then jumped by 40.41% to $9.7 million in 2025, then climbed by 0.39% to $9.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $9.7 million in Q1 2026, $9.7 million in Q4 2025, and $5.3 million in Q3 2025.